Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

Yulia A. Desheva, Galina F. Leontieva, Tatiana A. Kramskaya, Galina O. Landgraf, Ivan A. Sychev, Andrey R. Rekstin, Alexander N. Suvorov

Research output

1 Citation (Scopus)

Abstract

We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.

Original languageEnglish
Article numbere01154
JournalHeliyon
Volume5
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Influenza Vaccines
Human Influenza
Streptococcus agalactiae
Peptides
Infection
Immunoglobulin M
H7N9 Subtype Influenza A Virus
Immunization
Vaccination
Viruses
Interferon Type I
Orthomyxoviridae
Vaccines
Protective Factors
Cytokines
Lung
Antibodies
Serum

Scopus subject areas

  • General

Cite this

@article{bd111263454b46d5bece9c0d5c3c7ffd,
title = "Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection",
abstract = "We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20{\%} of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.",
keywords = "Immunology, Microbiology, Vaccines, Virology",
author = "Desheva, {Yulia A.} and Leontieva, {Galina F.} and Kramskaya, {Tatiana A.} and Landgraf, {Galina O.} and Sychev, {Ivan A.} and Rekstin, {Andrey R.} and Suvorov, {Alexander N.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.heliyon.2019.e01154",
language = "English",
volume = "5",
journal = "Heliyon",
issn = "2405-8440",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Factors of early protective action of live influenza vaccine combined with recombinant bacterial polypeptides against homologous and heterologous influenza infection

AU - Desheva, Yulia A.

AU - Leontieva, Galina F.

AU - Kramskaya, Tatiana A.

AU - Landgraf, Galina O.

AU - Sychev, Ivan A.

AU - Rekstin, Andrey R.

AU - Suvorov, Alexander N.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.

AB - We are developing an associated vaccine based on live influenza vaccine (LAIV) and streptococcal recombinant peptides. The recombinant group B streptococcus (GBS) peptides P6 and ScaAB demonstrated a distinguished immunomodulating effect in THP-1 cells. The increase in IFN 1-alpha expression after ScaAB inoculation was similar to that against LAIV. We immunized mice intranasal using of A/H7N3 LAIV or/and ScaAB peptide. At day 5 after immunization, we detected serum IgM which reacted with non-vaccine influenza viruses. Associated vaccination of mice using LAIV and GBS peptide was the most effective against sub-lethal infection with A/H7N9 influenza virus and against lethal challenge with A/H1N1pdm virus at day 5 after immunization. Not only LAIV but also the ScaAB protected about 20% of the immunized animals against lethal challenge with A/H1N1pdm virus. The early protection was related to increasing type 1 interferons expression in the lungs. Our results in mice have shown that successful protection against homologous and heterologous influenza infections can be achieved soon after vaccination with either LAIV or LAIV in combination with GBS recombinant peptide. Presumably, such protection may be mediated by non-specific IgM antibodies and an increase in the expression of early cytokines in the airway.

KW - Immunology

KW - Microbiology

KW - Vaccines

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=85060994853&partnerID=8YFLogxK

U2 - 10.1016/j.heliyon.2019.e01154

DO - 10.1016/j.heliyon.2019.e01154

M3 - Article

AN - SCOPUS:85060994853

VL - 5

JO - Heliyon

JF - Heliyon

SN - 2405-8440

IS - 2

M1 - e01154

ER -